Inhibitor/Activator
| Cat.No. | Name | Information |
|---|---|---|
| M7224 | RS 504393 | RS 504393 is a highly selective CCR2 chemokine receptor antagonist, with IC50 values of 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors, respectively. |
| M1971 | Maraviroc | Maraviroc (UK-427857) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity and favorable pharmacological properties. |
| M50158 | LM-108 | LM-108 is a novel anti-CCR8 monoclonal antibody that efficiently eliminates tumor-associated Tregs in a mouse model through antibody-dependent cell-mediated cytotoxicity (ADCC) without affecting peripheral Tregs, showing potent anti-tumor activity, and can be used for tumor-related studies. |
| M49638 | CKLF1-C27 TFA | CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. |
| M49637 | CKLF1-C27 | CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. |
| M49447 | GS-1811 | GS-1811 is a monoclonal antibody targeting CCR8 that selectively removes tumor-infiltrating T regulatory cells with immunosuppressive effects in the tumor microenvironment, and can be used in studies related to solid tumors. |
| M49444 | BAY-3375968 | BAY-3375968 is a monoclonal antibody targeting the CCR8 receptor that selectively reduces CCR8-positive Tregs through antibody-dependent cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and can be used in studies related to solid tumors. |
| M49442 | BMS-986340 | BMS-986340 is a human immunoglobulin G1 (IgG1) non-fucosylated (NF) monoclonal antibody to CCR8 that targets, binds to, and blocks CCR8 activity on CCR8-positive tumor-infiltrating regulatory T-cells (Tregs) in tumor microenvironments (TMEs) and prevents chemokine ligand (CCL1-CCR8)-mediated signaling. |
| M41795 | CCR5 antagonist 5 | CCR5 antagonist 5 is a CCR5 antagonist. |
| M41794 | SB-649701 | SB-649701 is a potent human CCR8 antagonist, with a pIC50 of 7.7. |
| M40814 | Zelnecirnon | Zelnecirnon is an orally active CCR4 inhibitor that inhibits the recruitment of Th2 inflammatory immune cells to inflamed tissues and may be used in studies related to atopic dermatitis and asthma. |
| M40607 | CCR7 Ligand 1 | CCR7 Ligand 1 (CCR7-Cmp2105) is a human CC chemokine receptor 7 (CCR7) variant ligand and a potent intracellular CCR7 receptor variant antagonist with a Kd value of 3 nM. In addition, CCR7 Ligand 1 also inhibited CCL19 activation with an IC50 value of 7.3 μM. |
| M40560 | Tivumecirnon | Tivumecirnon is a potent CCR4 small molecule antagonist with antitumor activity that blocks regulatory T cells that interfere with an effective antitumor immune response. It can be used in melanoma related studies. |
| M40551 | Nifeviroc | Nifeviroc (nifeviroc) is an orally active CCR5 antagonist for use in HIV-1 infection studies. |
| M30699 | MK-0812 Succinate | MK-0812 Succinate is a potent and selective CCR2 antagonist with high affinity at CCR2. |
| M30691 | ML604086 | ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca2+ concentrations. |
| M30343 | Vicriviroc maleate | Vicriviroc maleate (SCH-417690 maleate; SCH-D maleate) is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC90s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU 570). |
| M30120 | Aplaviroc | Aplaviroc (AK 602), a SDP derivative, is a CCR5 antagonist, with IC50s of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW. |
| M30118 | Aplaviroc hydrochloride | Aplaviroc (AK 602) hydrochloride, a SDP derivative, is a CCR5 antagonist, with IC50s of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW. |
| M29124 | BI-6901 | BI 6901 is a potent, selective CCR10 antagonist (pIC50=9.0). BI 6901 shows high selectivity over other GPCRs, including a number of other chemokine receptors. BI 6901 is efficacious in the murine DNFB model of contact hypersensitivity and can be used for inflammation research. |
| M28125 | BI 639667 | BI 639667 (compound 19n), a third azaindazole series compound, is a CCR1 antagonist, with an IC50 of 1.8 nM in Ca2+ flux assay. |
| M28040 | ALK4290 | ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor, with a Ki of 3.2 nM for hCCR3. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
